This research undertakes a review of available studies to conduct a critical analysis of the impact of patent protection in developing health care innovations and further on public health in India and the UK.
A patent is an intellectual property right that is granted to an inventor of a product, to exclude others from manufacturing, selling, importing an invention without the permission of the inventor. It is a social contract whereby the patentee is granted a monopoly over their invention, and in return society receives innovation. Therefore, it is an incentive scheme to benefit inventors and society as a whole. There are several laws which regulate Patents, such as patent protection, increasing the life of a patent, reducing patentability standards and extending patent protection to undesirable products increase monopolies. The patent owners gain exclusive rights in the form of patents or an exclusive license, thus leading to an increase in the cost of such products. In addition, the patent owners adopt strategies to extend the scope of patent gain additional patents which protect the underlying ingredient of the medicine. Many pharmaceutical products are protected by Patents. The generic drug manufacturers in the pharmaceutical industry are affected such laws, which in turn affects the price of medicines available to patients. This creates a problem of access to affordable means of healthcare and further affects public health.
Finally, the research will provide recommendations such as a framework of price control model to ensure sufficient access to medicines, and other recommendation for future of the progressing patent system of both the countries.
Table of Contents
INTRODUCTION: PATENTS AND HEALTH CARE
CHAPTER I:PATENT LAW IN INDIA AND UK
CHAPTER II:IMPLEMENTATION OF TRIPS FLEXIBILITIES
CHAPTER III:FRAMEWORKS FOR BALANCING RIGHTS TO ACCESS TO MEDICINES AND INTERESTS OF PHARMACEUTICAL COMPANIES
RECOMMENDATIONS
CONCLUSION: SAVING NATIONAL INTEREST?
Research Objectives and Key Themes
This dissertation aims to conduct a comparative analysis of the patent regimes in India and the UK to examine how they reconcile the enforcement of patent rights with the fundamental right to health. It explores how both nations utilize the flexibilities provided by the TRIPS agreement to balance the interests of pharmaceutical patent holders with the public's need for affordable access to essential medicines, ultimately seeking to propose a framework for improved legislative and judicial practices.
- Comparative analysis of patent legislation in India (Patents Act 1970) and the UK (Patents Act 1977).
- Implementation of TRIPS flexibilities, including compulsory licensing and parallel importation.
- Evaluation of "evergreening" strategies and their impact on generic competition and public health.
- Development of frameworks for price control and improved access to affordable pharmaceutical therapies.
Excerpt from the Book
Comparison of Statutory Patent Law of India and UK
The minimum standards of patent protection were prescribed under the TRIPS agreement and the member nations were required to follow the same. India has been a member of the WTO since 1995 and therefore required to comply with the provisions of the TRIPS Agreement. India was therefore bound to make patents available for products or process, or any kind of invention in all fields of technology. For which, several amendments were introduced in the Indian Patent Law. One of them was the Patent (Amendment) Act 2005, through which product patent was introduced as well as provisions in relation to pre-grant and post grant oppositions in granting of patent were modified. By means of this amendment product patent was extended to all fields of technology which included pharmaceutical drugs. Along with these safeguards, the Drug Price Control Order 1970 was also introduced which provided for a limit on the price of drugs by setting a maximum price for which the drug should be made available.
The current legislation in UK in relation to patents consists of the Patents Act 1977 as amended by the Copyright, Designs and Patents Act 1988 and then by Patents Act 2004, Subsequently amended by the Patents (Compulsory Licensing and Supplementary Protection Certificates) Regulations 2007. The primary effect of the Patents Act 1977 is to bring the patent law of UK closer to the European trading partners, in compliance with the provisions of European Patent Convention (EPC). The criteria for patentability in UK is derived from the EPC.
An invention is patentable if it is new, involves an inventive step and is capable of industrial application. According to the Patent Act 1977 an invention shall be considered to involve an innovative step if it is ‘not obvious to a person skilled in the art’.
Summary of Chapters
INTRODUCTION: PATENTS AND HEALTH CARE: Provides the foundational context of global intellectual property standards under TRIPS and introduces the central tension between pharmaceutical patent monopolies and the protection of public health.
CHAPTER I:PATENT LAW IN INDIA AND UK: Compares the statutory foundations of patent law in both jurisdictions, focusing on patentability requirements and the specific legislative amendments aimed at balancing patent protection with healthcare access.
CHAPTER II:IMPLEMENTATION OF TRIPS FLEXIBILITIES: Analyzes how courts and governments in India and the UK utilize TRIPS-compliant mechanisms like compulsory licensing, opposition proceedings, and parallel importation to regulate pharmaceutical market behavior.
CHAPTER III:FRAMEWORKS FOR BALANCING RIGHTS TO ACCESS TO MEDICINES AND INTERESTS OF PHARMACEUTICAL COMPANIES: Proposes structural solutions and models, such as price control mechanisms and tiered pricing, to reconcile the economic interests of pharmaceutical companies with the necessity of affordable healthcare.
RECOMMENDATIONS: Outlines specific policy and legal adjustments for both the UK and India to refine their patent systems and improve the efficacy of public health protections.
CONCLUSION: SAVING NATIONAL INTEREST?: Synthesizes the comparative findings and reinforces the necessity of adapting patent frameworks to national development needs while ensuring human rights are respected.
Keywords
Patent Protection, TRIPS Agreement, Compulsory Licensing, Pharmaceutical Industry, Access to Medicines, Evergreening, Public Health, Intellectual Property Rights, Patentability, Generic Medicines, Indian Patent Act, UK Patents Act, Parallel Importation, Competition Law, Healthcare Infrastructure
Frequently Asked Questions
What is the core focus of this research?
The paper examines the impact of patent protection on healthcare in India and the UK, focusing on how these two nations balance the rights of pharmaceutical patent holders with the public's right to access affordable medicines.
What are the primary themes discussed?
Key themes include the implementation of TRIPS flexibilities, the challenge of "evergreening" pharmaceutical patents, the role of national patent laws in India and the UK, and strategies for pricing and market competition.
What is the central research question?
The research asks how India and the UK interpret and enforce patent laws to comply with TRIPS while simultaneously safeguarding public health, and what frameworks can be adopted to balance these competing interests.
Which methodologies are employed in the study?
The dissertation utilizes a doctrinal research approach, analyzing statutes, relevant case law, international agreements like TRIPS, and academic literature concerning intellectual property and public health.
What is the significance of the patent regimes compared?
The study highlights how India (a developing nation) and the UK (a developed nation) have different healthcare infrastructure and socio-economic needs, which necessitates tailored approaches to patent enforcement and medicine access.
Which terms characterize this work?
The work is characterized by terms such as compulsory licensing, evergreening, pharmaceutical innovation, generic competition, and TRIPS flexibilities.
How does the Indian patent system differ from the UK regarding opposition?
India allows for pre-grant opposition, where the person filing the opposition becomes a formal party to the proceedings, providing an added advantage in effectively stating objections, unlike the UK system.
What is the impact of "evergreening" on public health?
Evergreening allows pharmaceutical companies to extend patent life on existing drugs through minor modifications, which can inhibit generic competition and maintain high prices, thereby limiting access to affordable medicine.
Why is the PPRS relevant to the UK healthcare model?
The Pharmaceutical Price Regulation Scheme (PPRS) acts as a mechanism in the UK to control the overall profits of pharmaceutical companies and limit excessive price increases for branded medicines.
What role does the National Health Service (NHS) play in this analysis?
The NHS serves as the primary client of the pharmaceutical industry in the UK, and its payment arrangements and healthcare infrastructure provide a different regulatory context compared to India's out-of-pocket healthcare system.
- Citation du texte
- Priyanka Jain (Auteur), 2017, The Impact of Patent Protection on Health Care in India and the UK. A Comparative Analysis, Munich, GRIN Verlag, https://www.grin.com/document/512487
